Maxillomandibular advancement for the treatment of obstructive sleep apnoea syndrome: a long-term follow-up

Obstructive sleep apnoea syndrome (OSAS), which is characterised by repetitive episodes of pharyngeal collapse during sleep, is gaining much attention because of the important deleterious consequences it might have on the patient's health. We therefore organised a retrospective longitudinal study to report the long-term follow-up of maxillomandibular advancement (MMA) as a treatment for OSAS. A total of 19 patients with severe OSAS was treated during the period 2007–2016. They were followed up six months postoperatively (T1) and after a mean follow up of 6.7 (range 4-10) years (T2, between November 2017 and February 2018) for the polysomnography variables, and the Epworth sleeping scale (ESS) and body mass index (BMI) were recorded. All polysomnographic variables improved significantly from baseline to T1 and from baseline to T2. The ESS significantly improved from baseline to T2. Nearly all patients at T1 and over two-thirds at T2 had a 50% reduction of the apnoea/hypopnoea index when compared with baseline, and a value lower than 20 of the same index. The BMI did not change significantly from T0 to T2. Our long-term follow-up has documented the stability of the outcomes of the MMA for the treatment OSAS.